SCHEMBL2957973

SCHEMBL2957973

COC(=O)c1cc(OC)cc(C(=O)NC2CCNCC2)c1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.62
KMT2A Q03164 1/20 0.62
HPGDS O60760 1/20 0.55
ATM Q13315 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
ALDH1A1 P00352 1/20 0.52
HTR4 Q13639 2/20 0.51
LMNA P02545 1/20 0.49
MCHR1 Q99705 6/20 0.48
MAPK1 P28482 1/20 0.47
OPRK1 P41145 1/20 0.47
SMYD3 Q9H7B4 3/20 0.47
GAA P10253 1/20 0.46
CNR1 P21554 1/20 0.45
KCNH2 Q12809 1/20 0.45
AURKB Q96GD4 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4590660 0.86 MEN1 (0.62) MEN1KMT2AHPGDSATML3MBTL1
SCHEMBL4590657 0.86 MEN1 (0.62) MEN1KMT2AHPGDSATML3MBTL1
Hydrochloric Acid SCHEMBL2954893 0.85 MEN1 (0.60) MEN1KMT2AHPGDSATML3MBTL1
SCHEMBL2953714 0.83 MEN1 (0.58) MEN1KMT2AHPGDSATML3MBTL1
SCHEMBL1711687 0.81 ALDH1A1 (0.63) MEN1KMT2AHPGDSALDH1A1HTR4
SCHEMBL29530916 0.81 ALDH1A1 (0.63) MEN1KMT2AHPGDSALDH1A1HTR4
SCHEMBL2470064 0.81 MEN1 (0.84) MEN1KMT2AATML3MBTL1ALDH1A1
SCHEMBL2963930 0.80 MEN1 (0.57) MEN1KMT2AHPGDSATML3MBTL1
SCHEMBL18396293 0.80 HPGDS (0.62) MEN1KMT2AHPGDSHTR4SMYD3
Hydrochloric Acid SCHEMBL31722313 0.80 ALDH1A1 (0.62) MEN1KMT2AHPGDSALDH1A1HTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772253-B2 Amide derivatives as somatostatin receptor 5 antagonists HOFFMAN-LA ROCHE INC. (US) 2010-08-10 US disclosed
EP-1893603-B1 PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2009-10-14 EP disclosed
EP-1893603-A1 PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2008-03-05 EP disclosed
WO-2006128803-A1 PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-12-07 WO disclosed
US-20060276508-A1 Amide derivatives as somatostatin receptor 5 antagonists F. HOFFMANN-LA ROCHE AG (CH) 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276508-A1 Amide derivatives as somatostatin receptor 5 antagonists SSTR5, SSTR3, SSTR1 MEN1 528/4885KMT2A 3271/4885HPGDS 2883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.